NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Acute Lymphoblastic LeukemiaB-cell Non Hodgkin LymphomaPre B-Cell Acute Lymphoblastic Leukaemia

Interventions

DRUG

Blinatumomab 9ug

Cycle 1 - Days 1-7: 9 ug/day IV daily

DRUG

Blinatumomab 28 ug

Cycle 1 - Days 8-28: 28 ug/day IV daily

DRUG

Blinatumomab

Cycle 2 - Days 1-28: 28 ug/day IV daily

DRUG

Dexamethasone

Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV

Trial Locations (1)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore